Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open-label, Follow-up Study to Evaluate the Long-term Safety and Tolerability of BGG492 TID as Adjunctive Therapy in Patients With Partial Onset Seizures Completing Double-blind, Placebo-controlled Study CBGG492A2207 or CBGG492A2211.

Next Previous
Trial Profile

A Multicenter, Open-label, Follow-up Study to Evaluate the Long-term Safety and Tolerability of BGG492 TID as Adjunctive Therapy in Patients With Partial Onset Seizures Completing Double-blind, Placebo-controlled Study CBGG492A2207 or CBGG492A2211.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Mar 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Selurampanel (Primary)
  • Indications Partial epilepsies
  • Focus Adverse reactions
  • Sponsors Novartis; Novartis Pharmaceuticals

Most Recent Events

  • 13 May 2017 Results of a double-blind phase II dose-titration study (core study-NCT01147003), post-hoc analysis of the core study and open-label-extension study (NCT01338805), published in the Epilepsia Journal.
  • 18 Jul 2012 Additional lead trial investigators identified as reported by ClinicalTrials.gov.
  • 04 Jul 2012 Status changed from recruiting to completed in Hungary, Germany and Slovakia, according to the European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top